LIFESTAT - Living with statins: An interdisciplinary project on the use of statins as a cholesterol-lowering treatment and for cardiovascular risk reduction.

Published on Jul 1, 2016in Scandinavian Journal of Public Health1.761
· DOI :10.1177/1403494816636304
Christa Lykke Christensen3
Estimated H-index: 3
(UCPH: University of Copenhagen),
Jørn Wulff Helge41
Estimated H-index: 41
(UCPH: University of Copenhagen)
+ 15 AuthorsFlemming Dela47
Estimated H-index: 47
(UCPH: University of Copenhagen)
Aim: LIFESTAT is an interdisciplinary project that leverages approaches and knowledge from medicine, the humanities and the social sciences to analyze the impact of statin use on health, lifestyle and well-being in cohorts of Danish citizens. The impetus for the study is the fact that 10% of the population in the Scandinavian countries are treated with statins in order to maintain good health and to avoid cardiovascular disease by counteracting high blood levels of cholesterol. The potential benefit of treatment with statins should be considered in light of evidence that statin use has prevalent and unintended side effects (e.g. myalgia, and glucose and exercise intolerance). Methods: The LIFESTAT project combines invasive human experiments, biomedical analyses, nationwide surveys, epidemiological studies, qualitative interviews, media content analyses, and ethnographic participant observations. The study investigates the biological consequences of statin treatment; determines the mechanism(s) by which st...
  • References (25)
  • Citations (6)
📖 Papers frequently viewed together
58 Citations
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Barry A. Franklin (Beaumont Hospital)H-Index: 40
#2Carl J. LavieH-Index: 84
12 CitationsSource
#1Paul T. Williams (LBNL: Lawrence Berkeley National Laboratory)H-Index: 72
#2Paul D. Thompson (Hartford Hospital)H-Index: 87
Abstract Objectives To determine whether decreases in exercise 1) were greater in individuals who were diagnosed as having hypercholesterolemia than in those without the diagnosis during follow-up and 2) were greater in incident hypercholesterolemic participants starting statins than in those not treated with cholesterol-lowering medications. Participants and Methods Regression analyses of changes since baseline (Δ) in exercise vs diagnosis of hypercholesterolemia and its treatment in 66,377 run...
17 CitationsSource
#1Miguel Cainzos-Achirica (Johns Hopkins University)H-Index: 14
#2Chintan S. Desai (Johns Hopkins University)H-Index: 10
Last. Seth S. Martin (Johns Hopkins University)H-Index: 32
view all 8 authors...
The 2013 American College of Cardiology/American Heart Association cardiovascular disease prevention guidelines represent an important step forward in the risk assessment and management of atherosclerotic cardiovascular disease in clinical practice. Differentiated risk prediction equations for women and black individuals were developed, and convenient 10-year and lifetime risk assessment tools were provided, facilitating their implementation. Lifestyle modification was portrayed as the foundatio...
14 CitationsSource
#1Tom J.J. Schirris (Radboud University Nijmegen)H-Index: 5
#2G. Herma Renkema (Radboud University Nijmegen)H-Index: 23
Last. Frans G. M. Russel (Radboud University Nijmegen)H-Index: 49
view all 13 authors...
Cholesterol-lowering statins effectively reduce the risk of major cardiovascular events. Myopathy is the most important adverse effect, but its underlying mechanism remains enigmatic. In C2C12 myoblasts, several statin lactones reduced respiratory capacity and appeared to be strong inhibitors of mitochondrial complex III (CIII) activity, up to 84% inhibition. The lactones were in general three times more potent inducers of cytotoxicity than their corresponding acid forms. The Qo binding site of ...
81 CitationsSource
#1Jessica L. Mega (Brigham and Women's Hospital)H-Index: 32
#2Nathan O. Stitziel (WashU: Washington University in St. Louis)H-Index: 23
Last. Marc S. Sabatine (Brigham and Women's Hospital)H-Index: 90
view all 17 authors...
Summary Background Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy. Methods A community-based cohort study (the Malmo Diet and Cancer Study) and four randomised controlled trials of both primary prevention (JUPITER and ASCOT) ...
217 CitationsSource
#1Erik S. G. Stroes (AMC: Academic Medical Center)H-Index: 19
#2Paul D. Thompson (Hartford Hospital)H-Index: 87
Last. Henry N. Ginsberg (Columbia University)H-Index: 82
view all 26 authors...
Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of...
464 CitationsSource
#1Joanne E. Mallinson (University of Nottingham)H-Index: 8
#2Kanagaraj Marimuthu (University of Nottingham)H-Index: 7
Last. Paul L. Greenhaff (University of Nottingham)H-Index: 54
view all 8 authors...
Statins are associated with muscle myalgia and myopathy, which probably reduce habitual physical activity. This is particularly relevant to older people who are less active, sarcopaenic and at increased risk of statin myalgia. We hypothesised that statin myalgia would be allied to impaired strength and work capacity in older people, and determined whether differences aligned with divergences in lean mass, protein turnover, insulin sensitivity and the molecular regulation of these processes. Knee...
18 CitationsSource
#1Scott M. GrundyH-Index: 171
#2Hidenori Arai (Kyoto University)H-Index: 48
Last. Dong Zhao (Capital Medical University)H-Index: 30
view all 17 authors...
Abstract An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non-high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic...
250 CitationsSource
#1Steen Larsen (UCPH: University of Copenhagen)H-Index: 28
#2Nis Stride (UCPH: University of Copenhagen)H-Index: 7
Last. Flemming Dela (UCPH: University of Copenhagen)H-Index: 47
view all 9 authors...
Background A prevalent side effect of statin therapy is muscle pain, and yet the basic mechanism behind it remains unknown. We hypothesize that a statin-induced reduction in muscle Q10 may attenuate mitochondrial OXPHOS capacity, which may be an underlying mechanism. Methods Plasma glucose and insulin concentrations were measured during an oral glucose tolerance test. Mitochondrial OXPHOS capacity was measured in permeabilized muscle fibers by high-resolution respirometry in a crosssectional des...
92 CitationsSource
#1Borislava MihaylovaH-Index: 18
#2Jonathan EmbersonH-Index: 47
Last. T Sourjina (USYD: University of Sydney)H-Index: 3
view all 120 authors...
BACKGROUND Statins reduce LDL cholesterol and prevent vascular events, but their net effects in people at low risk of vascular events remain uncertain. METHODS This meta-analysis included individual participant data from 22 trials of statin versus control (n=134,537; mean LDL cholesterol difference 1·08 mmol/L; median follow-up 4·8 years) and five trials of more versus less statin (n=39,612; difference 0·51 mmol/L; 5·1 years). Major vascular events were major coronary events (ie, non-fatal myoca...
1,394 CitationsSource
Cited By6
#1Paul L. Greenhaff (NIHR: National Institute for Health Research)H-Index: 54
#2Joanne Mallinson (NIHR: National Institute for Health Research)
Last. Flemming Dela (UCPH: University of Copenhagen)H-Index: 47
view all 3 authors...
Animal models of overt statin myopathy reveal clear negative effects on muscle protein and carbohydrate metabolism, which appear to be linked to changes in Akt/FOXO signalling. Forcibly increasing muscle carbohydrate flux under these conditions by pharmacological means blocks statin myopathy. Human volunteer research has delivered less definitive mechanistic insight of the aetiology of statin-related metabolic dysregulation, with little evidence of profound changes in muscle protein and carbohyd...
#1Anja Birk Kuhlman (UCPH: University of Copenhagen)H-Index: 4
#2Thomas Morville (UCPH: University of Copenhagen)H-Index: 3
Last. Flemming Dela (UCPH: University of Copenhagen)H-Index: 47
view all 7 authors...
Simvastatin is a cholesterol-lowering drug that is prescribed to lower the risk of cardiovascular disease following high levels of blood cholesterol. There is a possible risk of new onset diabetes mellitus with statin treatment but the mechanisms behind are unknown. Coenzyme Q10 (CoQ10) supplementation has been found to improve glucose homeostasis in various patient populations and may increase muscle GLUT4 content. Our aim was to investigate whether eight weeks of CoQ10 supplementation can impr...
1 CitationsSource
#1Tine Lovsø Dohlmann (UCPH: University of Copenhagen)H-Index: 4
#2Thomas Morville (UCPH: University of Copenhagen)H-Index: 3
Last. Steen Larsen (UCPH: University of Copenhagen)H-Index: 28
view all 7 authors...
1 CitationsSource
#1Sofie Rosenlund Lau (UCPH: University of Copenhagen)H-Index: 3
#2John Sahl Andersen (UCPH: University of Copenhagen)H-Index: 14
Last. Bjarke Oxlund (UCPH: University of Copenhagen)H-Index: 4
view all 4 authors...
This article provides a socio-historical account of the rise of preventive medicine in Denmark by exploring details of how pharmaceutical cholesterol-reduction became routinized as a standard of care. While other accounts of mass-prevention with statins primarily focus on the role of the pharmaceutical industry, we aim to show how routinization in a welfare state with free access to healthcare and where direct-to consumer advertisement is prohibited bring to the fore other actors and entities th...
1 CitationsSource
#1Maria Hansen (UCPH: University of Copenhagen)H-Index: 3
#2Anja Birk Kuhlman (UCPH: University of Copenhagen)H-Index: 4
Last. Flemming Dela (UCPH: University of Copenhagen)H-Index: 47
view all 10 authors...
Abstract Purpose Atherosclerosis is a major risk factor for cardiovascular disease (CVD) and is known to be an inflammatory process. Statin therapy decreases both cholesterol and inflammation and is used in primary and secondary prevention of CVD. However, a statin induced decrease of plasma concentrations of the antioxidant coenzyme Q10 (CoQ10), may prevent the patients from reaching their optimal anti-inflammatory potential. Here, we studied the anti-inflammatory effect of Simvastatin therapy ...
3 CitationsSource
2 CitationsSource
#1Margit Kriegbaum (UCPH: University of Copenhagen)H-Index: 12
#2Sofie Rosenlund Lau (UCPH: University of Copenhagen)H-Index: 3
Abstract Background Statins are widely prescribed to lower cardiovascular morbidity and mortality. However, statin non-adherence is very high. Purpose The aim of this paper was to investigate reasons for stopping statin treatment in the general population and to study how aspects of information-seeking and processing is associated with statin non-adherence. Methods This study used a population survey on 3050 Danish residents aged 45–65 years. Reasons for statin discontinuation was studied among ...
1 CitationsSource